Dyne Therapeutics, Inc. - 8-K Filing
Dyne Therapeutics held its 2026 Annual Meeting of Stockholders on June 5, 2026, where shareholders elected three Class III directors (David Lubner, Brian Posner, Jason Rhodes), approved executive compensation on a non-binding advisory basis with 93.8% in favor, and passed amendments to increase authorized shares from 200 million to 400 million and provide for officer exculpation. (Items: 5.07 Submission of Matters to a Vote of Security Holders)
Tickers: $DYN